ArticleMedicine2026
Retrospective analysis of bleeding risk with tirofiban in patients with acute ischemic stroke and diabetes mellitus.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to explore the risk of overall extracranial bleeding events with tirofiban in patients with acute ischemic stroke (AIS) and diabetes mellitus and analyze the impact of blood glucose control on this risk. A single-center retrospective cohort study design was used, including 100 patients with AIS and diabetes mellitus admitted between April 2023 and November 2025. Propensity score matching was used to divide patients into the tirofiban group (50 cases) and the control group (50 cases). The primary outcome was the incidence of overall extracranial bleeding events within 7 days after medication administration. Secondary outcomes included types of extracranial bleeding (e.g., gingival bleeding), thrombocytopenia, and neurological function outcomes. Multivariable logistic regression and subgroup analysis were conducted to assess independent risk factors. The incidence of overall extracranial bleeding events in the tirofiban group was 32.0%, significantly higher than the 16.0% in the control group (risk ratio = 2.00, 95% confidence interval = 1.11-3.60, P = .021). Gingival bleeding (10.0% vs 2.0%, P = .047) and thrombocytopenia (10.0% vs 2.0%, P = .047) occurred more frequently in the tirofiban group. Multivariable analysis showed that tirofiban treatment (adjusted odds ratio = 2.45, P = .018) and admission random blood glucose (adjusted odds ratio = 1.22, P = .032) were independent risk factors for overall extracranial bleeding events. Subgroup analysis revealed that in patients with hemoglobin A1c ≥7.5%, the bleeding risk associated with tirofiban was higher (odds ratio = 3.33, 95% confidence interval = 1.05-10.56, P-interaction = .04). In patients with AIS and diabetes mellitus, tirofiban treatment did not significantly increase the risk of intracranial hemorrhage, but it significantly raised the risk of extracranial bleeding events (especially gingival bleeding) and thrombocytopenia. This risk was more pronounced in patients with poor blood glucose control. Comprehensive monitoring of bleeding signs and enhanced glucose management are required in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.